With Ebola still rampaging across West Africa and cases popping up in the United States, it’s clear that the virus is now a financial event.
That means we need to think about this logically.
And we also need to invest logically.
Over the past few weeks, we’ve watched as one “clinical stage” pharma firm after another has seen its stock price rise and plummet on rumors about who has the most likely Ebola vaccine.
I’m not taking you on any wild rides like that.
Instead, I want to introduce you to a solid big-cap company that is gearing up for a major Ebola drug trial and could have a product out in just seven months – and it would likely see hefty gains when its drug hits the market.